Scholarlink

Background <p>Adherence to cysteamine in nephropathic cystinosis (NC) remains challenging. A better adherence with delayed-release (DR) compared to immediate-release (IR) cysteamine at 1&#xa0;year was previously shown. This study aimed to evaluate adherence to DR cysteamine at 2&#xa0;years.</p> Methods <p>Treatment adherence was assessed using a medication event monitoring system; adherence ranged from 0 (poor) to 2 (good). Leukocyte cystine level was measured at each 3-month visit. Long-term follow-up data (7&#xa0;years after the end of the study) on self-reported adherence and quality of life was also obtained in a sub-group of patients.</p> Results <p>Seventeen patients with NC under DR cysteamine from three French centers were included at a median age of 13.9 (5.4–33.0) years. The median adherence score was 1.62 (0.03–1.98) over the 2-year follow-up, with 65% of patients having good adherence and 75% having partial or good adherence. No significant difference in leukocyte cystine level between baseline and 2&#xa0;years was found (0.8&#xa0;nmol vs. 0.4&#xa0;nmol, respectively; difference in median of − 1.0&#xa0;nmol; 95% CI − 0.7, 0.4; <i>P</i> = 0.64). Long-term follow-up data highlighted that no patient wished to switch back to IR cysteamine, as taking the medication twice rather than four times a day was easier.</p> Conclusions <p>This study found a fairly good adherence to DR cysteamine over time. Decreasing the number of intakes per day may improve adherence and limit the side effects of the drug, representing an additional argument in favor of its use in patients with cystinosis.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adherence to delayed-release cysteamine in nephropathic cystinosis over time: data from the prospective CrYSTobs cohort study

  • 期刊论文

  • 发表日期：

    2025年2月4日

查看全文
  • Chloé Grosyeux,
  • Ségolène Gaillard,
  • Denis Morin,
  • Julien Hogan,
  • Cécile Acquaviva-Bourdain,
  • Justine Bacchetta,
  • Aurélia Bertholet-Thomas

摘要

Background

Adherence to cysteamine in nephropathic cystinosis (NC) remains challenging. A better adherence with delayed-release (DR) compared to immediate-release (IR) cysteamine at 1 year was previously shown. This study aimed to evaluate adherence to DR cysteamine at 2 years.

Methods

Treatment adherence was assessed using a medication event monitoring system; adherence ranged from 0 (poor) to 2 (good). Leukocyte cystine level was measured at each 3-month visit. Long-term follow-up data (7 years after the end of the study) on self-reported adherence and quality of life was also obtained in a sub-group of patients.

Results

Seventeen patients with NC under DR cysteamine from three French centers were included at a median age of 13.9 (5.4–33.0) years. The median adherence score was 1.62 (0.03–1.98) over the 2-year follow-up, with 65% of patients having good adherence and 75% having partial or good adherence. No significant difference in leukocyte cystine level between baseline and 2 years was found (0.8 nmol vs. 0.4 nmol, respectively; difference in median of − 1.0 nmol; 95% CI − 0.7, 0.4; P = 0.64). Long-term follow-up data highlighted that no patient wished to switch back to IR cysteamine, as taking the medication twice rather than four times a day was easier.

Conclusions

This study found a fairly good adherence to DR cysteamine over time. Decreasing the number of intakes per day may improve adherence and limit the side effects of the drug, representing an additional argument in favor of its use in patients with cystinosis.

Graphical abstract